Product Reports Resources Pricing Login Book a demo

Nurix

Biotech & Life Sciences · San Francisco, United States · Founded 2012 · IPO 2020

Nurix Therapeutics is a biotechnology company focused on discovering and developing drugs that harness the natural process of protein degradation to treat a wide range of diseases. The company's core technology revolves around controlling ubiquitin E3 ligases, which are key enzymes responsible for protein breakdown in human cells. By targeting these enzymes, Nurix aims to develop novel therapeutic agents, particularly in the field of oncology, including small molecule immuno-oncology agents. Nurix operates in the biopharmaceutical market, primarily serving patients with cancer and other serious diseases. The company employs a business model that involves drug discovery and development, with revenue generated through partnerships, licensing agreements, and potential future sales of its proprietary drugs. Keywords: biotechnology, protein degradation, ubiquitin E3 ligases, oncology, immuno-oncology, drug discovery, therapeutic agents, cancer treatment, biopharmaceutical, small molecules.

Valuation $2.02B
Revenue $84M
Total funding $100–500M
Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Investors

8 investors on Nurix's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage
The Column Group
Third Rock Ventures
Series B+ 6 investors entered at this stage
Foresite Capital
Boxer Capital
Wellington Management
Redmile Group
EcoR1 Capital
Bain Capital Life Sciences

Global footprint

Where Nurix has talent and traffic

Workforce by country
6 countries with
team presence
🇺🇸 United States98%
🇵🇹 Portugal0.7%
🇬🇧 United Kingdom0.3%
🇫🇷 France0.3%
🇧🇩 Bangladesh0.3%
Top 5 of 6 shown
Web traffic by country
16K monthly visits
across markets
🇺🇸 United States64.4%
🇮🇳 India15%
🇯🇵 Japan5%
🇨🇦 Canada4.4%
🇪🇸 Spain4.4%
Top 5 markets shown

Talent graph

The shape of Nurix's talent

Dealroom maps Nurix's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

7 standout operatorsDealroom-flagged across the org
4 AI specialistsincl. 3 core researchers
377 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Nurix's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$31M patent portfolio · 38 active families

Estimated portfolio value
$31M
1.6% of market cap · 4.5× smaller than top peer Exelixis ($140M)
38 active patent families
Where Nurix innovates Cancer researchCarcinosisDiseaseImmune systemKinase

Where Nurix concentrates vs peers

Each axis is a top-10 topic across Nurix and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Nurix

An AI-synthesized read of the highest-engagement posts about Nurix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nurix on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles